Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Power Ultrasound and the Production of Mesoscopic Particles and Aqueous Dispersions
The authors discuss advanced sonocrystallization particle-engineering techniques for manufacturing mesoscopic particles.


Pharmaceutical Technology


16. X. Chen et al., "Rapid Dissolution of High-Potency Danazol Particles Produced by Evaporative Precipitation into Aqueous Solution," J. Pharm. Sci. 93 (7), 1867–1878 (2004).

17. X. Chen et al., "Preparation of Cyclosporine A Nanoparticles by Evaporative Precipitation into Aqueous Solution," Int. J. Pharm. 242 (1–2), 3–14 (2002).

18. University of Bath, Process for the Production of Particles, Patent WO/2004/073827, 2004.

19. R. Price, J.S. Kaerger, "Processing of Spherical Crystalline Particles via a Novel Solution Atomization and Crystallization by Sonication (SAXS) Technique," Pharm. Res. 21 (2), 372–381 (2004).

20. G. Ruecroft, "Power Ultrasound and Particle Engineering: Crystals for Drug Delivery and Formulation," Chim. Oggi 25 (3), 12–14 (2007).

21. G. Ruecroft, "Sound, Science, and Crystals: Improved Crystallization and Particle Engineering," Screening 2 34–36 (2007).

22. M. Hannay et al., "Overcoming the Challenges of Developing Combination Products in Different Inhalation Device Platforms," Respiratory Drug Del. 319 (2008).

23. Prosonix Limited, Process and Apparatus for Irradiating Fluids, Patent WO/2000/35579, 2000.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here